NAT1 genotypic and phenotypic contribution to urinary bladder cancer risk: a systematic review and meta-analysis

References

• Arylamine N-acetyltransferase Gene Nomenclature Committee. 2016. Human NAT1 Alleles (Haplotypes). Komotini, Greece: Democritus University of Thrace; [accessed 2016 May 8]. http://nat.mbg.duth.gr/background_2013.html#_NAT_nomenclature
   Google Scholar
• Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. 1995. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res. 55:5230–5237.
   PubMed Web of Science ®Google Scholar
• Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. 1995. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res. 55:5226–5229.
   PubMed Web of Science ®Google Scholar
• Boukouvala S, Hein DW, Grant DM, Sim E, Minchin R, Agundez JAG, Rodrigues-Lima F. 2016. The database of arylamine N-acetyltransferases (NATs). Alexandroupolis, Greece: Democritus University of Thrace. [accessed 2016 May 8]. http://nat.mbg.duth.gr/
   Google Scholar
• Broberg K, Björk J, Paulsson K, Höglund M, Albin M. 2005. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 26:1263–1271.
   PubMed Web of Science ®Google Scholar
• Bruhn C, Brockmoller J, Cascorbi I, Roots I, Borchert HH. 1999. Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol. 58:1759–1764.
   PubMed Web of Science ®Google Scholar
• Butcher NJ, Minchin RF. 2012. Arylamine N-acetyltransferase 1: a novel drug target in cancer development. Pharmacol Rev. 64:147–165.
   PubMed Web of Science ®Google Scholar
• Cantor KP, Villanueva CM, Silverman DT, Figueroa JD, Real FX, Garcia-Closas M, Malats N, Chanock S, Yeager M, Tardon A, et al. 2010. Polymorphisms in GSTT1, GSTZ1, and CYP2E1, disinfection by-products, and risk of bladder cancer in Spain. Environ Health Perspect. 118:1545–1550.
   PubMed Web of Science ®Google Scholar
• Carreón T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, et al. 2006. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer. 118:161–168.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Roots I, Brockmöller J. 2001. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res. 61:5051–5056.
   PubMed Web of Science ®Google Scholar
• Castelao JE, Yuan JM, Gago-Dominguez M, Skipper PL, Tannenbaum SR, Chan KK, Watson MA, Bell DA, Coetzee GA, Ross RK, et al. 2004. Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer. 110:417–423.
   PubMed Web of Science ®Google Scholar
• Cochrane C. 2014. Cochrane collaboration review manager version 5.3. Copenhagen, Denmark: The Nordic Cochrane Centre.
   Google Scholar
• Covolo L, Placidi D, Gelatti U, Carta A, Scotto Di Carlo A, Lodetti P, Piccichè A, Orizio G, Campagna M, Arici C, et al. 2008. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol. 23:355–362.
   PubMed Web of Science ®Google Scholar
• de Leon JH, Vatsis KP, Weber WW. 2000. Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1. Mol Pharmacol. 58:288–299.
   PubMed Web of Science ®Google Scholar
• Dhaini HR, Kobeissi L. 2014. Toxicogenetic profile and cancer risk in Lebanese. J Toxicol Environ Health B Crit Rev. 17:95–125.
   PubMed Web of Science ®Google Scholar
• Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I, Bray F. 2016. Cancer today. Lyon, France: International Agency for Research on Cancer. [accessed 2017 July 14]. http://gco.iarc.fr/today
   Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. 2015. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin D, Forman D, Bray F. 2014. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer.
   Google Scholar
• Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. 2011. Association between smoking and risk of bladder cancer among men and women. JAMA. 306:737–745.
   PubMed Web of Science ®Google Scholar
• Gago-Dominguez M, Bell DA, Watson MA, Yuan JM, Castelao JE, Hein DW, Chan KK, Coetzee GA, Ross RK, Yu MC. 2003. Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis. 24:483–489.
   PubMed Web of Science ®Google Scholar
• Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK. 2001. Use of permanent hair dyes and bladder-cancer risk. Int J Cancer. 91:575–579.
   PubMed Web of Science ®Google Scholar
• Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, et al. 2005. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 366:649–659.
   PubMed Web of Science ®Google Scholar
• Gong M, Dong W, An R. 2012. Glutathione S-transferase T1 polymorphism contributes to bladder cancer risk: a meta-analysis involving 50 studies. DNA Cell Biol. 31:1187–1197.
   PubMed Web of Science ®Google Scholar
• Gu J, Liang D, Wang Y, Lu C, Wu X. 2005. Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. Mutat Res. 581:97–104.
   PubMed Web of Science ®Google Scholar
• Hein D, Doll M, Fretland A, Leff M, Webb S, Xiao G, Devanaboyina U, Nangju N, Feng Y. 2000a. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphism. Cancer Epidemiol Biomarkers Prev. 9(January):29–42.
   PubMed Web of Science ®Google Scholar
• Hein D, McQueen C, Grant D, Goodfellow G, Kadlubar F, Weber W. 2000b. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber. Drug Metab Dispos. 28:1425.
   PubMed Web of Science ®Google Scholar
• Hohne S, Gerullis H, Blaszkewicz M, Selinski S, Hengstler JG, Otto T, Golka K. 2017. N-acetyltransferase 1*10 genotype in bladder cancer patients. J Toxicol Environ Health A. 80:417–422.
   PubMed Web of Science ®Google Scholar
• Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY, Chen CJ. 1999. Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer. 81:537–541.
   PubMed Web of Science ®Google Scholar
• Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, Gelatti U, Spaliviero M, Placidi D, Carta A, et al. 2004. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 110:598–604.
   PubMed Web of Science ®Google Scholar
• JaskuŁa-Sztul R, Sokołowski W, Gajȩcka M, Szyfter K. 2001. Association of arylamine N-acetyltransferase (NAT1 and NAT2) genotypes with urinary bladder cancer risk. J Appl Genet. 42:223–231.
   PubMedGoogle Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin. 61:69–90.
   PubMed Web of Science ®Google Scholar
• Jiang W, Feng Y, Hein D. 1999. Higher DNA adduct levels in urinary bladder and prostate of slow acetylator inbred rats administered 3,2′-dimethyl-4-aminobiphenyl. Toxicol Appl Pharmacol. 156:187–194.
   PubMed Web of Science ®Google Scholar
• Katoh T, Inatomi H, Yang M, Kawamoto T, Matsumoto T, Bell DA. 1999. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and risk of urothelial transitional cell carcinoma among Japanese. Pharmacogenetics. 9:401–404.
   PubMedGoogle Scholar
• Kogevinas M, Fernandez F, Garcia-Closas M, Tardon A, Garcia-Closas R, Serra C, Carrato A, Castano-Vinyals G, Yeager M, Chanock SJ, et al. 2006. Hair dye use is not associated with risk for bladder cancer: evidence from a case-control study in Spain. Eur J Cancer. 42:1448–1454.
   PubMed Web of Science ®Google Scholar
• Koutros S, Silverman DT, Baris D, Zahm SH, Morton LM, Colt JS, Hein DW, Moore LE, Johnson A, Schwenn M, et al. 2011. Hair dye use and risk of bladder cancer in the New England Bladder Cancer Study. Int J Cancer. 129:2894–2904.
   PubMed Web of Science ®Google Scholar
• Lacko M, Oude Ophuis MB, Peters WH, Manni JJ. 2009. Genetic polymorphisms of smoking-related carcinogen detoxifying enzymes and head and neck cancer susceptibility. Anticancer Res. 29:753–761.
   PubMed Web of Science ®Google Scholar
• Letašiová S, Medveďová A, Šovčíková A, Dušinská M, Volkovová K, Mosoiu C, Bartonová A. 2012. Bladder cancer, a review of the environmental risk factors. Environ Health. 11(Suppl 1):S11.
   PubMed Web of Science ®Google Scholar
• Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. 2000. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 343:78–85.
   PubMed Web of Science ®Google Scholar
• Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, et al. 2009. STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement. Genet Epidemiol. 33:581–598.
   PubMed Web of Science ®Google Scholar
• Mascarenhas R, Pietrzak M, Smith RM, Webb A, Wang D, Papp AC, Pinsonneault JK, Seweryn M, Rempala G, Sadee W. 2015. Allele-selective transcriptome recruitment to polysomes primed for translation: protein-coding and noncoding RNAs, and RNA isoforms. PLoS One. 10:e0136798.
   PubMed Web of Science ®Google Scholar
• McGrath M, Michaud D, De Vivo I. 2006. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. BMC Cancer. 6:239.
   PubMed Web of Science ®Google Scholar
• Meliker JR, Nriagu JO. 2007. Arsenic in drinking water and bladder cancer: review of epidemiological evidence. Trace Metals Other Contaminants Environ. 9:551–584.
   Google Scholar
• Millner LM, Doll MA, Stepp MW, States JC, Hein DW. 2012. Functional analysis of arylamine N-acetyltransferase 1 (NAT1) NAT1*10 haplotypes in a complete NATb mRNA construct. Carcinogenesis. 33:348–355.
   PubMed Web of Science ®Google Scholar
• Moch H, Humphrey PA, Ulbright TM, Reuter VE. 2016. WHO classification of tumours of the urinary system and male genital organs. 4th ed. Lyon, France: International Agency for Research on Cancer.
   Google Scholar
• Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, Johnson AT, Lubin JH, Hein DW, Dagnall CL, et al. 2011. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England Bladder Cancer Study and NAT2 meta-analysis. Carcinogenesis. 32:182–189.
   PubMed Web of Science ®Google Scholar
• Mostafa MH, Sheweita SA, O'Connor PJ. 1999. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev. 12:97–111.
   PubMed Web of Science ®Google Scholar
• Murta-Nascimento C, Silverman DT, Kogevinas M, Garcia-Closas M, Rothman N, Tardon A, Garcia-Closas R, Serra C, Carrato A, Villanueva C, et al. 2007. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev. 16:1595–1600.
   PubMed Web of Science ®Google Scholar
• Okkels H, Sigsgaard T, Wolf H, Autrup H. 1997. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev. 6:225–231.
   PubMed Web of Science ®Google Scholar
• Ovsiannikov D, Selinski S, Lehmann ML, Blaszkewicz M, Moormann O, Haenel MW, Hengstler JG, Golka K. 2012. Polymorphic enzymes, urinary bladder cancer risk, and structural change in the local industry. J Toxicol Environ Health A. 75:557–565.
   PubMed Web of Science ®Google Scholar
• Payton MA, Sim E. 1998. Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants. Biochem Pharmacol. 55:361–366.
   PubMed Web of Science ®Google Scholar
• Perera FP. 1998. Molecular epidemiology of environmental carcinogenesis. Recent Results Cancer Res. 154:39–46.
   PubMedGoogle Scholar
• Rodriguez-Antona C, Donato MT, Pareja E, Gomez-Lechon MJ, Castell JV. 2001. Cytochrome P-450 mRNA expression in human liver and its relationship with enzyme activity. Arch Biochem Biophys. 393:308–315.
   PubMed Web of Science ®Google Scholar
• Rossini A, de Almeida Simao T, Albano RM, Pinto LF. 2008. CYP2A6 polymorphisms and risk for tobacco-related cancers. Pharmacogenomics. 9:1737–1752.
   PubMed Web of Science ®Google Scholar
• Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, Grumet S, Perera FP. 2000. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis. 21:1281–1289.
   PubMed Web of Science ®Google Scholar
• Salazar-Gonzalez RA, Turijan-Espinoza E, Hein DW, Nino-Moreno PC, Romano-Moreno S, Milan-Segovia RC, Portales-Perez DP. 2017. Arylamine N-acetyltransferase 1 in situ N-acetylation on CD3+ peripheral blood mononuclear cells correlate with NATb mRNA and NAT1 haplotype. Arch Toxicol. [accessed 2017 Oct 17]. DOI: 10.1007/s00204-017-2082-y
   PubMed Web of Science ®Google Scholar
• Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. 2017. Bladder cancer. Vol. 3. New York: Macmillan Publishers Limited.
   Google Scholar
• Sato M, Sato T, Izumo T, Amagasa T. 1999. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis. 20:1927–1931.
   PubMed Web of Science ®Google Scholar
• Schroeder JC, Conway K, Li Y, Mistry K, Bell DA, Taylor JA. 2003. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res. 63:7530–7538.
   PubMed Web of Science ®Google Scholar
• Smelt VA, Mardon HJ, Sim E. 1998. Placental expression of arylamine N-acetyltransferases: evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2. Pharmacol Toxicol. 83:149–157.
   PubMedGoogle Scholar
• Stiborova M, Levova K, Barta F, Shi Z, Frei E, Schmeiser HH, Nebert DW, Phillips DH, Arlt VM. 2012. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol Sci. 125:345–358.
   PubMed Web of Science ®Google Scholar
• Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR. 2015. N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis. Antimicrob Agents Chemother. 59:4129–4138.
   PubMed Web of Science ®Google Scholar
• Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL, Bell DA. 1998. The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene–gene-exposure three-way interaction. Cancer Res. 58:3603–3610.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 2015. Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108.
   PubMed Web of Science ®Google Scholar
• Vatsis K, Weber W. 1993. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus . Arch Biochem Biophys. 301:71–76.
   PubMed Web of Science ®Google Scholar
• Vaziri SA, Hughes NC, Sampson H, Darlington G, Jewett MAS, Grant DM. 2001. Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. Pharmacogenetics. 11:7–20.
   PubMedGoogle Scholar
• Walker K, Ginsberg G, Hattis D, Johns D, Guyton K, Sonawane B. 2009. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health B Crit Rev. 5–6:440–472.
   Web of Science ®Google Scholar
• Wang D, Para MF, Koletar SL, Sadee W. 2011. Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet Genomics. 21:652–664.
   PubMed Web of Science ®Google Scholar
• Weber W, Vatsis K. 1993. Individual variability in p-aminobenzoic acid N-acetylation by human N-acetyltranferase (NAT1) of peripheral blood. Pharmacogenetics. 3:209–212.
   PubMedGoogle Scholar
• Windmill K, Gaedigk A, Hall P, Samaratunga H, Grant D, McManus M. 2000. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci. 54:19–29.
   PubMed Web of Science ®Google Scholar
• Wu K, Wang X, Xie Z, Liu Z, Lu Y. 2013. N-acetyltransferase 1 polymorphism and bladder cancer susceptibility: a meta-analysis of epidemiological studies. J Int Med Res. 41:31–37.
   PubMed Web of Science ®Google Scholar
• Yang M, Katoh T, Delongchamp R, Ozawa S, Kohshi K, Kawamoto T. 2000. Relationship between NAT1 genotype and phenotype in a Japanese population. Pharmacogenetics. 10:225–232.
   PubMedGoogle Scholar
• Yassine IA, Kobeissi L, Jabbour ME, Dhaini HR. 2012. N-acetyltransferase 1 (NAT1) genotype: a risk factor for urinary bladder cancer in a Lebanese population. J Oncol. 2012:1–10.
   Google Scholar
• Yu MC, Skipper PL, Tannenbaum SR, Chan KK, Ross RK. 2002. Arylamine exposures and bladder cancer risk. Mutat Res. 506–507:21–28.
   PubMed Web of Science ®Google Scholar
• Yuan JM, Chan KK, Coetzee GA, Castelao JE, Watson MA, Bell DA, Wang R, Yu MC. 2008. Genetic determinants in the metabolism of bladder carcinogens in relation to risk of bladder cancer. Carcinogenesis. 29:1386–1393.
   PubMed Web of Science ®Google Scholar
• Zeegers M, Kellen E, Buntinx F, van den Brandt P. 2004. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 21:392–401.
   PubMed Web of Science ®Google Scholar
• Zhang KY, Gao LJ, Wu YQ, Chen JY, Lin CG, Liang SH, Su JX, Ye JM, He XY. 2015. NAT1 polymorphisms and cancer risk: a systematic review and meta-analysis. Int J Clin Exp Med. 8:9177–9191.
   PubMed Web of Science ®Google Scholar
• Zheng J, Chen S, Jiang L, You Y, Wu D, Zhou Y. 2011. Functional genetic variations of cyclooxygenase-2 and susceptibility to acute myeloid leukemia in a Chinese population. Eur J Haematol. 87:486–493.
   PubMed Web of Science ®Google Scholar
• Zheng YL, Amr S, Saleh DA, Dash C, Ezzat S, Mikhail NN, Gouda I, Loay I, Hifnawy T, Abdel-Hamid M, et al. 2012. Urinary bladder cancer risk factors in Egypt: a multicenter case-control study. Cancer Epidemiol Biomarkers Prev. 21:537–546.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hein DW. 2008. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J. 8:339–348.
   PubMed Web of Science ®Google Scholar
• Zhu Y, States JC, Wang Y, Hein DW. 2011. Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3′ untranslated regions. Birth Defects Res A Clin Mol Teratol. 91:77–84.
   PubMed Web of Science ®Google Scholar